本帖最后由 老马 于 2013-3-13 13:43 编辑 + ?% ^5 m: u" d6 U& A
2 s, n1 e0 c' E! f2 \健择（吉西他滨）+顺铂+阿瓦斯汀
- ]* }" j o, V' W# U |3 T Gemzar +Cisplatin + Avastin$ Y( o/ Z" A5 o7 ?! q! s0 ?1 S* g
http://annonc.oxfordjournals.org/content/21/9/1804.full$ p+ [' M8 u ?6 X9 Q* B
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: a7 L, d+ }: Q+ J6 VPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. " S( N9 M9 i% m+ |4 Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; B+ ]; h6 q6 G1 _" w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 893)
3 D8 Y# K7 s; j2 G8 l
华为网盘附件：. {( C$ t" F" ~) m2 I2 C
【华为网盘】ava.JPG
5 Q6 b! e& ?" ]. A. d4 y" e |
显身卡
